Skip to main content

Advertisement

Table 3 Multivariate regression analyses of motor complications correlates among 737 L-dopa/DCI users

From: Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China

Variable Dyskinesias P Value Motor fluctuations P Value
  Yes / no OR (95% CI)   Yes / no OR (95% CI)  
Age at onset (yr) ≥59 30 / 420 Reference 0.15 68 / 382 Reference 0.13
  <45 11 / 49 2.32 (1.00 – 5.41)   14 / 46 1.20 (0.57 – 2.53)  
  45-58 22 / 205 1.31 (0.70 – 2.46)   55 / 172 1.63 (1·02 – 2·61)  
PD duration (yr) <5 15 / 399 Reference 0.36 30 / 384 Reference 0.02
  5-9 28 / 188 1.88 (0.79 – 4.51)   64 / 152 2.52 (1.31 – 4.85)  
  ≥10 20 / 87 1.82 (0.59 – 5.59)   43 / 64 2.46 (1.05 – 5.76)  
Hoehn -Yahr stage <3 38 / 540 Reference 0.03 76 / 502 reference <0.001
  ≥3 35 / 134 2.03 (1.08 – 3.82)   61 / 98 2.58 (1.62 – 4.11)  
LD dose, mg/d <400 16 / 370 Reference 0.02 39 / 347 Reference 0.002
  400-599 21 / 149 2.48 (1.20 – 5.13)   37 / 133 1.69 (0.99 – 2.91)  
  ≥600 26 / 155 2.44 (1.20 – 4.98)   61 / 120 2.48 (1.49 – 4.14)  
LD/DCI duration (yr) <2 14 / 294 Reference 0.44 23 / 285 Reference 0.07
  2-4 15 / 215 1.04 (0.47 – 2.34)   36 / 194 1.58 (0.86 – 2.87)  
  ≥5 34 / 165 1.73 (0.66 – 4.51)   78 / 121 2.42 (1.14 – 5.12)  
Months to initiate ≤12 27 / 339 Reference 0.87 66 / 300 Reference 0.66
LD/DCI use >12 36 / 439 0.95 (0.49 – 1.83)   71 / 300 0.89 (0.54 – 1.48)  
Initial treatment non LD/DCI 22 / 119 Reference 0.04 35 / 106 Reference 0.42
  LD/DCI only 22 / 259 0.46 (0.22 – 0.95)   53 / 228 0.76 (0.42 – 1.36)  
  LD/DCI + others 19 / 296 0.41 (0.19 – 0.87)   49 / 266 0.67 (0.37 – 1.22)  
  1. Abbreviations: LD, L-dopa; DCI, decarboxylase Inhibitor; OR, odds ratios; CI, confidence interval.
  2. Model adjusted for gender, age at onset, PD duration, Hoehn -Yahr stage, levodoap dose, LD/DCI duration, region, months to initiate LD/DCI use, and initial treatment.